Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

(“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing ...

Alzheimer’s Therapeutics MarketThe global Alzheimer’s therapeutics market is projected to experience significant growth, with an expected valuation of USD 3,052.3 million in 2023. The market is ...

‘Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection’ by Eugene P. Duff et al. was published in Nature Medicine at 10:00 UK time on Thursday 30th January.

Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments ...

The methylation of plasma cell-free DNA (cfDNA) has emerged as a valuable diagnostic and prognostic biomarker in various cancers including colorectal cancer (CRC). Currently, there are no biomarkers ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...